To further investigate whether NANOG expression in tumor cells modulates the immune feature of the TME, we treated CT26 P3 tumor–bearing mice with intravenously administered chitosan nanoparticles carrying a Nanog- or GFP-targeting siRNA along with anti–PD-1 (Supplemental Figures 9 and 10). The gene discussed is NANOG; the disease is neoplasm.